
Amarin Corporation plc (NASDAQ:AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations.
The update follows the ongoing global impact of COVID-19 and the uncertainty resulting from the impact of generic icosapent ethyl (IPE) availability in the U.S. and challenges for most drugs seeking market access in Europe.